Learn how Hematology Oncology Associates of Central New York reduced administrative burden and observed treatment patterns by implementing Flatiron Assist™, the oncology-specific, clinical decision support tool.
Improvements within six-month observation period
-
100% relative use of preferred regimens for small-cell lung cancer
-
96% relative use of preferred regimens for esophageal cancer
-
94% relative use of preferred regimens for pancreatic cancer
The Solution: Implementing an oncology-specific, clinical decision support tool
In May 2020, Hematology Oncology Associates of Central New York adopted Flatiron Assist™ to empower their physicians and provide up-to-date, evidence-based treatment options at the point of care.
Within 14 months, 84% of all clinicians within the practice were creating orders within Flatiron Assist™, reducing administrative burden throughout the practice by solidifying platform use.
Flatiron worked hand-in-hand with clinicians and regularly sought feedback from them, which allowed the practice to better streamline processes as additional disease categories were rolled out. Specific feedback from clinicians, in terms of pathway utilization, helped to identify areas for additional clinician support and education.
The outcome: Better understanding treatment patterns
We asked Olivia Barrett, the Healthcare Business Analyst at Hematology Oncology Associates of Central New York, how working with Flatiron Assist™ improved the practice’s data reporting insights.
“First, it has allowed us to better understand our treatment patterns across patient populations. The related Flatiron Assist™ data, such as: pathway utilization, concordance rates and preferred regimen utilization rates is powerful data, and can increase awareness and spark important conversations between physicians.
Further, the robust Flatiron Assist™ dataset allows us to look at outcomes associated with certain treatment regimens and patient populations, facilitating the development of tailored interventions and promoting higher quality care.”
The value: Enhancing clinical data to participate in Value-Based Care program
Since beginning this partnership in 2020, Flatiron Assist™ has provided enhanced reporting capabilities that have added value throughout the Hematology Oncology Associates of Central New York practice.
Flatiron Assist™ has helped practices make an impact on participation in the ASCO & COA Patient-Centered Cancer Care Certification. The ASCO-COA Oncology Medical Home (OMH) pilot program recognizes the importance of evidence-based clinical pathways in advancing the delivery of high-value care and optimizing patient outcomes. Hematology Oncology Associates of Central New York’s participation in OMH has helped drive the development of a governance process for the management and oversight of Flatiron Assist™ utilization and compliance, and Flatiron Assist has allowed HOA to seamlessly report the required metrics for the OMH pilot program.
Your evidence-based, oncology-specific clinical decision support tool
Want to learn how Flatiron Assist™ prioritizes evidence-based medicine and clinical research at the point of care while driving value across cancer centers?
